<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154504</url>
  </required_header>
  <id_info>
    <org_study_id>CEP1781/07</org_study_id>
    <nct_id>NCT01154504</nct_id>
  </id_info>
  <brief_title>The Role of Adrenomedullin on the Outcome of Severe Heart Failure: a Clinical Randomized Study</brief_title>
  <official_title>The Role of Adrenomedullin on the Outcome of Severe Heart Failure: a Clinical Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Study Hypothesis:

             -  The decrease of plasma adrenomedullin (ADM) concentration by ultrafiltration and
                isovolumetric hemofiltration in patients with acute III and IV Class New York Heart
                Association Functional(NYHA) heart failure is more pronounced than a standard
                diuretic treatment and is related with clinical improvement.

        2. Outcome Measurements:

      To correlate the adrenomedullin plasma levels with clinical treatment, ultrafiltration and
      hemofiltration related to:

        -  Brain natriuretic peptide (BNP) level

        -  angiotensin II level

        -  sympathetic nervous activity

        -  oxydative stress

        -  clinical outcome at the beginning, at discharge and 90 days after randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Testing the hypothesis that adrenomedullin (ADM) is a important peptide in severe heart
      failure and that is related to clinical condition, we will study the effects of 3 different
      treatments (clinical usual treatment,ultrafiltration and isovolumetric hemofiltration with
      diuretics) to participants are followed until discharge to Adrenomedullin level and clinical
      outcomes,and also their relationship with angiotensin II level, brain natriuretic
      peptide(BNP), sympathetic nervous system and oxydative stress.

      The patients will be randomized in three different treatment group and analyzed in three
      moments: on the randomization, at discharge and 90 days after randomization(plus or minus 3).

      The clinical treatment will be optimized, the ultrafiltration will be done until clinically
      adequate fluid removal or until hematocrit increased 10% from basal level, and isovolumetric
      hemofiltration will be done for 8 hours- dose of 35 ml/kg/h in association with diuretic. All
      this dialytic procedures will be done with PAES membrane- filter HF1400 and automatic
      machine.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We randomized 18 patients, but was impossible to measure adrenomedullin in Brazil. However, we
    analysed some interesting clinical and laboratorial results.
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of Adrenomedullin plasma in different treatments- clinical,ultrafiltration and isovolumetric hemofiltration</measure>
    <time_frame>90 days after randomization (plus or minus 3 days).</time_frame>
    <description>The adrenomedullin level will be compared in three different treatments: clinical treatment, ultrafiltration treatment and isovolumetric hemofiltration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of Adrenomedullin plasma in different treatments- clinical,ultrafiltration and isovolumetric hemofiltration</measure>
    <time_frame>at discharge</time_frame>
    <description>The adrenomedullin level will be compared in three different treatments: clinical treatment, ultrafiltration treatment and isovolumetric hemofiltration. The patients will be followed until discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Adrenomedullin plasma levels in three different treatment approaches will be related to clinical outcome.</measure>
    <time_frame>at discharge</time_frame>
    <description>The correlation of adrenomedullin plasma levels in all 3 arms related to optimized clinical outcome. The patients will be followed until discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Adrenomedullin plasma levels in three different treatment approaches will be related to clinical outcome.</measure>
    <time_frame>90 days after randomization (plus or minus 3)</time_frame>
    <description>The correlation of adrenomedullin plasma levels in all 3 arms related to optimized clinical outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Adrenomedullin plasma levels in three different treatment approaches will be related to oxydative stress</measure>
    <time_frame>at discharge</time_frame>
    <description>The correlation of adrenomedullin plasma levels in all 3 arms related to oxydative stress. The patients will be followed until discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Adrenomedullin plasma levels in three different treatment approaches will be related to oxydative stress</measure>
    <time_frame>90 days after randomization(plus or minus 3)</time_frame>
    <description>The correlation of adrenomedullin plasma levels in all 3 arms related to oxydative stress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Adrenomedullin plasma levels in three different treatment approaches will be related to angiotensin II plasma level</measure>
    <time_frame>at discharge</time_frame>
    <description>The correlation of adrenomedullin plasma levels in all 3 arms related to angiotensin II level. The patients will be followed until discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Adrenomedullin plasma levels in three different treatment approaches will be related to angiotensin II plasma level</measure>
    <time_frame>90 days after randomization(plus or minus 3)</time_frame>
    <description>The correlation of adrenomedullin plasma levels in all 3 arms related to angiotensin II plasma level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Adrenomedullin plasma levels in three different treatment approaches will be related to Brain natriuretic peptide plasma level</measure>
    <time_frame>at discharge</time_frame>
    <description>The correlation of adrenomedullin plasma levels in all 3 arms related to Brain natriuretic peptide level. The patients will be followed until discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Adrenomedullin plasma levels in three different treatment approaches will be related to Pro-Brain natriuretic peptide plasma level</measure>
    <time_frame>90 days after randomization(plus or minus 3)</time_frame>
    <description>The correlation of adrenomedullin plasma levels in all 3 arms related to Brain natriuretic peptide level, 90 days after randomization(plus or minus 3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Adrenomedullin plasma levels in three different treatment approaches will be related to sympathetic nervous system activity</measure>
    <time_frame>at discharge</time_frame>
    <description>The correlation of adrenomedullin plasma levels in all 3 arms related to sympathetic nervous system.The patients will be followed until discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Adrenomedullin plasma levels in three different treatment approaches will be related to sympathetic nervous system activity</measure>
    <time_frame>90 days after randomization(plus or minus 3)</time_frame>
    <description>The correlation of adrenomedullin plasma levels in all 3 arms related to sympathetic nervous system.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>clinical treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with previous diagnosis of decompensated III and IV Heart Failure will be included. The clinical treatment will be optimized.
Clinical assessment, Adrenomedullin, Angiotensin II, Brain Natriuretic Peptide, oxydative stress, sympathetic nervous system activity will be evaluated at the beginning, at discharge and 90 days after randomization(plus or minus3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ultrafiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ultrafiltration will be done on decompensated patients III and IV acute heart failure on Intensive Care Unit. This patients will have biochemical analysis, adrenomedullin, angiotensin II,Brain Natriuretic Peptide, oxydative stress measurements,sympathetic nervous system activity evaluated and clinical outcome analyzed at the beginning,at discharge and 90 days after randomization(plus or minus 3).
Diuretic will be withdrawn during ultrafiltration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isovolumetric hemofiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this group will have isovolumetric hemofiltration on Intensive Care Unit. They will have biochemical analysis, Adrenomedullin plasmatic level, Brain Natriuretic Peptide Level, Angiotensin II level, Oxydative stress measurement,sympathetic nervous system, and clinical outcome evaluated at the study beginning,at discharge and 90 days after randomization(plus or minus 3).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical treatment</intervention_name>
    <description>The clinical treatment will be optimized to gold standard international heart failure treatment</description>
    <arm_group_label>clinical treatment</arm_group_label>
    <other_name>adrenomedullin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrafiltration</intervention_name>
    <description>The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.</description>
    <arm_group_label>ultrafiltration</arm_group_label>
    <other_name>dialysis</other_name>
    <other_name>adrenomedullin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>isovolumetric hemofiltration</intervention_name>
    <description>The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.</description>
    <arm_group_label>isovolumetric hemofiltration</arm_group_label>
    <other_name>hemofiltration</other_name>
    <other_name>dialysis</other_name>
    <other_name>adrenomedullin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more than two item:

               -  more than eighteen years of age

               -  orthopnea

               -  Chest Rx with cardiomegaly and pulmonary infiltration

               -  edema

               -  diuretic resistance

        Exclusion Criteria:

          -  insulin dependent diabetes

          -  hepatic cirrhosis

          -  vascular access problems

          -  creatinine more than 2,5 mg/dl before acute heart failure

          -  systemic infection

          -  aortic stenosis and heart transplantation

          -  radiologic contrast up to 72 hours prior randomization

          -  advanced neoplasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto de Cardiologia</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>94801970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Anna Stein</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>adrenomedullin</keyword>
  <keyword>heart failure</keyword>
  <keyword>ultrafiltration</keyword>
  <keyword>hemofiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
    <mesh_term>Adrenomedullin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

